15 January 2021 in International Journal Of Impotence Research
12 May 2023 in BJUI Compass
Background: Prostate‐specific membrane antigen (PSMA)‐positron emission tomography/contrast‐enhanced computed tomography (PET/CT) is a sensitive imaging modality for prostate cancer (PCa). Due to lack of knowledge of the patient benefit, PSMA‐PET/CT is not yet recommended in the European guidelines for staging and treatment planning of patients with newly diagnosed PCa. We will investigate the potential difference in progression‐free survival (PFS) and quality of life (QoL) of using PSMA‐PET/CT versus sodium fluoride (NaF)‐PET/CT for staging and treatment planning in patients with newly diagnosed PCa.Study Design: This is a prospective randomised controlled multicentre trial carried out at three centres in the Region of Southern Denmark.Endpoints: The primary endpoint is PFS. Secondary endpoints are residual disease, stage migration, impact on treatment strategies, stage distribution, QoL and diagnostic accuracy measures.Patients and Methods: Patients eligible for the study have newly diagnosed unfavourable intermediate‐ or high‐risk PCa. A total of 448 patients will be randomised 1:1 into two groups: (A) a control group staged with Na[18F]F‐PET/CT and (B) an intervention group staged with [18F]PSMA‐1007‐PET/CT. A subgroup in the intervention group will have a supplementary blinded Na[18F]F‐PET/CT performed for the purpose of performing accuracy analyses. QoL will be assessed at baseline and with regular intervals (3–12 months) during the study period. Treatment decisions are achieved at multidisciplinary team conferences based on the results of the respective scans and according to current Danish guidelines.Trial Registration: The Regional Committees on Health Research Ethics for Southern Denmark (S‐20190161) and the Danish Medicines Agency (EudraCT Number 2021‐000123‐12) approved the study, and it has been registered on clinicaltrials.gov (Record 2020110469).
5 January 2023 in International Journal of Urological Nursing
MHMalene Grubbe Hildebrandt
Malene Grubbe Hildebrandt
How do patients, newly diagnosed with prostate cancer, experience their health‐related quality of life? There are numerous treatment options, all affecting health‐related quality of life in different ways. How each treatment method affects patients is used when guiding these patients in the choice of treatment. However, we are missing knowledge about how the newly diagnosed patient specifically experiences the first year of treatment, supporting the decision making. Therefore, this review aimed to provide evidence on how newly diagnosed prostate cancer patients experience their health‐related quality of life during the first year after their diagnosis, regardless of treatment choice. This review was performed in 2021 (renewed in 2022) in medline, cinahl, and embase. Studies showing the results for newly diagnosed patients with PC were included. A total of 12 studies were included. Across treatment types, sexual function was the most negatively affected domain, and emotional function was the domain with the most improvement from baseline to 12 months. Active surveillance seems to have similar to no impact on health‐related quality of life, radical proctectomy negatively impacts urinary function, external beam radiotherapy mostly has a negative impact on bowel function, and brachytherapy negatively impacts urinary function. Across treatment types, sexual function was the most negatively affected domain, and emotional function was the domain with the most improvement from baseline to 12 months. This knowledge can be used by urologists and nurses when guiding newly diagnosed patients in how the early part of treatment for prostate cancer is experienced.
25 January 2024 in Nordic Journal of Psychiatry
Online self-harming and suicidal behavior is a novel and rapidly increasing phenomenon warranting comprehensive mapping of used research methods. To identify and map how knowledge on online self-harming and suicidal behavior is gathered, including how data are collected e.g. questionnaires and interviews. The review follows the Joanna Briggs Institute Manual for Scoping Reviews in tandem with Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. A keyword search of three electronic databases was conducted on two occasions, yielding 5422 records. Following duplicate removal, the records were screened based on the following inclusion criterions; (1) in English or Nordic language and published between 2011-2022, (2) presenting results for self-harming and/or suicidal behavior on social media and (3) using tools for either interview or questionnaire aiming at assessment of the experience of online self-harming and suicidal behavior from the perspective of the person who engages in the behavior. A total of 64 articles were included. 45 used questionnaires, 17 used interviews, and two studies mixed the two approaches. 17% of the studies had made some effort to ensure validity within the questionnaires and 15.8% gave full access to the interview guide. Research into online self-harming and suicidal behavior is characterized by a lack of validated measurements and methodological transparency. The results emphasize a need for further development, testing, and validation of questionnaires and greater openness and reflexivity in qualitative methodology to enable cross-study comparison and advance knowledge of this complex phenomenon.
19 April 2023 in International Journal of Urological Nursing
4 March 2026 in Scandinavian Journal of Urology
Objective: This study aimed to compare test sensitivity for detecting aggressive prostate cancer and test specificity (measured by reduction in prostate biopsies) between algorithm-triage and standard systematic biopsy in elderly men with suspected prostate cancer. Methods: This randomised controlled trial enrolled men ≥ 70 years old suspected of prostate cancer and randomised them 1:1 to algorithm-triage or standard systematic biopsies. The algorithm arm used a 10-gene mRNA panel from urine and plasma samples, integrated with clinical characteristics and PSA measurements to predict prostate cancer with International Society of Urological Pathology grade group ≥ 2. Patient-reported outcomes measures were collected using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores or subdomains throughout a 24-month follow-up. ClinicalTrials.gov: NCT04079699. Results: A total of 202 men were included between October 2019 and September 2021. The study was terminated early due to algorithm underperformance. The algorithm-triage arm detected fewer indolent cancers (7.9% vs. 19%, absolute difference −10.9 percentage points, 95% confidence interval [CI]: −21.0 to −1.0 pp, P = 0.039) but also fewer clinically significant cancers (26% vs. 40%, absolute difference −13.9 percentage points, 95% CI: −27.6 to −0.1 pp, P = 0.051) compared to systematic biopsy. Patient-reported outcomes showed no significant between-group differences in FACT-P scores or subdomains throughout 24-month follow-up (differences 0.1–2.2 points, all P > 0.05), indicating comparable quality of life. Conclusion: The biomarker-based algorithm-triage reduced biopsy numbers but also detected fewer clinically significant prostate cancers. Quality of life was comparable between approaches.